Memantina Krka

Memantine, the active ingredient in Memantina Krka, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults. GNH USA supplies Memantina Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantina Krka is a NMDA‑receptor antagonist used in the management of Alzheimer’s disease. - Moderate to severe Alzheimer’s disease: helps maintain cognition and daily functioning in patients with established disease.

Memantina Krka may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate pain in the head region. - Constipation: reduced bowel movements or hard stools. - Fatigue: feeling unusually tired or weak. - Nausea: sensation of queasiness or urge to vomit.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Severe allergic reactions: rash, swelling, or difficulty breathing. - Hepatic dysfunction: abnormal liver enzyme elevations. - Stevens‑Johnson syndrome: rare skin blistering disorder. - Suicidal thoughts: emergence of depressive or suicidal ideation.

When prescribing Memantina Krka, clinicians should consider several safety aspects. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Concomitant NMDA antagonists: avoid combined use to reduce risk of additive neurotoxicity. - History of seizures: monitor closely for increased seizure activity. - Pregnancy and breastfeeding: safety not established; use only if potential benefit justifies potential risk. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Memantina Krka can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: concurrent use may increase central nervous system side effects. - Other NMDA antagonists: additive neurotoxic risk. - Strong CYP450 inhibitors (e.g., quinidine): may raise memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Loop diuretics (e.g., furosemide): can elevate memantine levels. - Anticholinesterase inhibitors: monitor for enhanced therapeutic or adverse effects. - Alcohol: may exacerbate dizziness and sedation.